{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:13Z","timestamp":1785769573843,"version":"3.56.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) has rapidly evolved from a research tool to a clinically applicable biomarker in colorectal cancer (CRC), transforming the assessment of minimal residual disease (MRD) and recurrence risk. The growing availability of commercial assays has complicated test selection and interpretation, particularly for gastroenterologists who increasingly encounter ctDNA data in postoperative and surveillance settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of the literature using PubMed, Embase, and Cochrane databases from January 2015 through March 2026, prioritizing randomized controlled trials, prospective cohort studies, and clinical practice guidelines relevant to ctDNA applications in CRC. The search employed predefined keyword combinations applied independently to each database. Two authors (A.S. and S.M.) independently screened titles and abstracts against the prespecified inclusion criteria, with disagreements resolved by discussion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tumor-informed assays that analyze patient-specific mutations exhibit high specificity for MRD detection, with serial sampling sensitivity reaching 88% compared to 59% for tumor-agnostic approaches, based on a 2026 systematic review and diagnostic accuracy meta-analysis that pooled data across multiple platforms and settings; the authors note substantial study-level heterogeneity in platform design and patient populations, and results should be interpreted accordingly, but require tissue access and extended processing times. Tumor-agnostic tests are more rapid and accessible, incorporating genomic and epigenomic signals, though they exhibit site-specific sensitivity variations ranging from 100% for liver metastases to 40% for peritoneal recurrence and remain vulnerable to biological confounders such as clonal hematopoiesis (CH). Importantly, ctDNA interpretation is subject to additional biological limitations including tumor shedding variability by anatomical site and disease burden, the timing of sample collection relative to surgery or chemotherapy, platform-specific detection thresholds, and pre-analytical variables such as hemolysis and delayed plasma processing. Randomized evidence supports ctDNA-guided de-escalation of adjuvant therapy in stage II colon cancer, with 5-year follow-up from the DYNAMIC trial demonstrating comparable recurrence-free survival (88% vs. 87%) and overall survival (93.8% vs. 93.3%) despite reduced chemotherapy use. In stage III disease, ctDNA is strongly prognostic, but chemotherapy intensification based solely on molecular positivity has not improved outcomes. This review additionally addresses underexplored areas including ctDNA in rectal cancer and neoadjuvant therapy, the influence of microsatellite instability (MSI) status on assay performance, and disparities in ctDNA access across racial, socioeconomic, and geographic populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For gastroenterologists encountering ctDNA results in postoperative and surveillance settings, three principles should guide practice (i): match assay selection to clinical intent - tumor-informed platforms for MRD-directed adjuvant decisions, tumor-agnostic platforms when tissue is unavailable (ii); interpret results within biological and technical context, accounting for platform-specific sensitivity limitations, biological confounders, and quantitative VAF trajectory rather than binary thresholds; and (iii) integrate ctDNA findings into multidisciplinary pathways - de-escalation is supported by high-quality randomized evidence in stage II disease (Grade A; Level I), while chemotherapy escalation based solely on ctDNA positivity in stage III disease is not supported outside clinical trials (Grade C; Level I). Standardization of assay performance benchmarks and equitable access to testing remain critical unmet needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1894198","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:13:12Z","timestamp":1785766392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA in colorectal cancer: assay selection, clinical applications, and practical integration for gastroenterologists"],"prefix":"10.3389","volume":"16","author":[{"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Hospital","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joecelyn Kirani","family":"Tan","sequence":"additional","affiliation":[{"name":"Faculty of Biology, The University of Manchester","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harendra","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadeep","family":"Dhali","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchir","family":"Paladiya","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Medicine","place":["Farmington, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvardhan","family":"Sisodia","sequence":"additional","affiliation":[{"name":"Mahatma Gandhi Memorial Medical College","place":["Indore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareesha","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"Royal Stoke University Hospital","place":["Stoke-on-Trent, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyant S.","family":"Dahiya","sequence":"additional","affiliation":[{"name":"The University of Kansas School of Medicine","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Mandal","sequence":"additional","affiliation":[{"name":"University of Nottingham School of Medicine","place":["Nottingham, United Kingdom"]},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham","place":["Nottingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.006","article-title":"Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy","volume":"36","author":"Martinez-Castedo","year":"2025","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103066","article-title":"Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis","volume":"142","author":"Camblor","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04030-w","article-title":"Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease: latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States","volume":"124","author":"Zavala","year":"2021","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12727","article-title":"Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy","volume":"14","author":"Chan","year":"2020","journal-title":"Mol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3335","article-title":"Characterization of plasma cell-free DNA variants as of tumor or clonal hematopoiesis origin in 16,812 advanced cancer patients","volume":"31","author":"Magee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0334282","article-title":"Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease","volume":"20","author":"Heo","year":"2025","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.1093","article-title":"Evaluation of comparative surveillance strategies of circulating tumor DNA, imaging, and CEA levels in patients with resected colorectal cancer","volume":"5","author":"Fakih","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.5","article-title":"Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II\/III study (abstract)","volume":"42","author":"Yothers","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in colorectal cancer patients","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4457","article-title":"Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review","volume":"8","author":"Krebs","year":"2022","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102170","article-title":"Clinical applications of cell-free DNA-based liquid biopsy analysis","volume":"51","author":"Yazaki","year":"2025","journal-title":"Transl Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100068","article-title":"Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients: hopes and limitations","volume":"4","author":"Soueidy","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.5394","article-title":"Applications of liquid biopsy for surgical patients with cancer: a review","volume":"159","author":"Mahuron","year":"2023","journal-title":"JAMA Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.3603","article-title":"Assessing the clinical utility of liquid biopsies across 5 potential indications from therapy selection to population screening: a review","volume":"183","author":"Carr","year":"2023","journal-title":"JAMA Intern Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf580","article-title":"Deep learning-based fusion of nuclear segmentation features for microsatellite instability and tumor mutational burden prediction in digestive tract cancers: a multicenter validation study","volume":"26","author":"Zhang","year":"2025","journal-title":"Brief Bioinform"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02300-3","article-title":"Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer","volume":"129","author":"Ryoo","year":"2023","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184547","article-title":"Clinical applications of minimal residual disease assessments by tumor-informed and tumor-uninformed circulating tumor DNA in colorectal cancer","volume":"13","author":"Gong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted next-generation sequencing of circulating tumor DNA for tracking minimal residual disease in localized colon cancer","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.2012.43.1718","article-title":"Use of research biopsies in clinical trials: are risks and benefits adequately discussed","volume":"31","author":"Overman","year":"2013","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clinbiochem.2021.03.005","article-title":"Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS\/NRAS\/BRAF genotyping for metastatic colorectal cancer","volume":"92","author":"Huang","year":"2021","journal-title":"Clin Biochem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04093-9","article-title":"Liquid biopsies across the cancer care continuum","volume":"31","author":"Landon","year":"2025","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:13:13Z","timestamp":1785766393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1894198"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1894198","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1894198"}}